Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases

$483,001ZIAFY2011AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 39018444 Paper 38657001 Paper 38411453 Paper 38383504 Paper 35969864 Paper 35939810 Paper 35935779 Paper 35817072 Paper 35679250 Paper 35605238 Paper 35580040 Paper 35298440 Paper 35093205 Paper 34928698 Paper 34632800 Paper 34125574 Paper 34050748 Paper 33709142 Paper 33534968 Paper 33485369 Paper 33460347 Paper 33399856 Paper 33356051 Paper 33232588 Paper 33215168 Paper 32976026 Paper 32678528 Paper 32445440 Paper 32395747 Paper 32197103 Paper 32109011 Paper 31923174 Paper 31541242 Paper 30926957 Paper 30855742 Paper 30561672 Paper 30104048 Paper 30032267 Paper 29746631 Paper 29020589 Paper 28958678 Paper 28522352 Paper 27043004 Paper 26908739 Paper 26768572 Paper 26768564 Paper 26219280 Paper 25961438 Paper 25957962 Paper 25830322 Paper 25742465 Paper 25004134 Paper 23468921 Paper 21593168 Paper 20375034 Paper 19569973 Paper 16672361 Paper 16192482 Paper 15955687 Paper 15288821 Paper 14999635 Paper 12627361

Abstract

Research in this project is currently focused on three areas. These are characterization of the survivors of the anthrax attacks of 2001;characterization of emerging respiratory infections including SARS and influenza;and development of novel therapies for flu. The anthrax study has enrolled a cohort of volunteers who are currently undergoing an extensive diagnostic evaluation. To be ready to deal with emerging infectious diseases of the respiratory tract, a protocol has been developed to systematically study patients presenting with a compatible symptom complex. This protocol has been complemented by the development of treatment protocols that will utilize hyperimmune plasma to the 2009 H1N1 virus or a combination of antiviral chemotherapeutic agents.

View original record on NIH RePORTER →